No Data
No Data
Express News | Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target
Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $70
Evercore analyst Liisa Bayko maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and adjusts the target price from $80 to $70.According to TipRanks data, the analyst has a success rate
Press Release: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $45 to $135
On Jul 19, major Wall Street analysts update their ratings for $Ultragenyx Pharmaceutical(RARE.US)$, with price targets ranging from $45 to $135.Evercore analyst Liisa Bayko maintains with a buy
Ultragenyx Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/18/2024 2.17% Wedbush $45 → $45 Reiterates Neutral → Neutral 06/12/2024 161.1% Cantor Fitzgerald $115 →
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Year to date, shares of Ultragenyx have lost 8.2% compared with the industry’s 1% decline.